Search Results 211-220 of 2430 for 2024embarking
The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA ...
Eight eligible Mayo Clinic hospitals earned A grades from The Leapfrog Group, an independent national nonprofit organization that provides safety ratings. All ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
A Study to Evaluate The Effectiveness and Safety of Abrocitinib, with or without Topical Medications, in Subjects Aged 12 Years and Older with Moderate-to- ...
ROCHESTER, Minn. — At Mayo Clinic, researchers published more than 10,000 scientific papers in 2024 that are driving medical discoveries, leading to new ...
Drugs used in chemotherapy, such as docetaxel, doxorubicin, cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from ...
This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
Mayo Clinic Comprehensive Cancer Center researchers spent 2024 mining patient data, leveraging artificial intelligence and conducting clinical trials to ...
The purpose of this study is to characterize pulmonary hemodynamic profiles, with a focus on PVR subtypes, in patients with left-sided valvular heart disease ...
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.